Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277358 | 0.86 | AAK1 (0.43) | MAPTHPGDNPC1SMN1; SMN2AAK1 | |
| SCHEMBL4628583 | 0.86 | CES2 (0.41) | HPGDNPC1SMN1; SMN2AAK1CYP2C9 | |
| SCHEMBL7860222 | 0.84 | PTPN2 (0.50) | MAPTHPGDNPC1SMN1; SMN2CYP2C9 | |
| SCHEMBL27298441 | 0.83 | CES2 (0.41) | MAPTHPGDNPC1SMN1; SMN2AAK1 | |
| SCHEMBL8143660 | 0.83 | HPGD (0.56) | MAPTHPGDSMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL6817695 | 0.81 | KDM4E (0.56) | MAPTHPGDNPC1SMN1; SMN2AAK1 | |
| SCHEMBL1185728 | 0.81 | USP30 (0.43) | MAPTHPGDNPC1SMN1; SMN2AAK1 | |
| SCHEMBL29517137 | 0.81 | KDM4E (0.56) | MAPTHPGDNPC1SMN1; SMN2AAK1 | |
| SCHEMBL4628585 | 0.81 | KDM4E (0.47) | MYCNR4A1KDM4EGLASORT1 | |
| SCHEMBL17215529 | 0.81 | CES2 (0.38) | HPGDNPC1SMN1; SMN2AAK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8791141-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8030334-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| EP-2307371-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082129-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | MAPT 1537/4885HPGD 546/4885NPC1 142/4885 |
| US-20100261698-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | MAPT 1537/4885HPGD 546/4885NPC1 142/4885 |
| US-20150210672-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | MAPT 1182/4885HPGD 569/4885NPC1 171/4885 |
| US-20140288126-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | MAPT 1182/4885HPGD 569/4885NPC1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.